Sequential efgartigimod-rituximab therapy in autoimmune nodopathy: A feasibility report on shortening the washout interval for B-cell depletion.
Benjian Sun, Lijia Zou, Jing Li et al.
✦ AI-curated · Sources linked
Case in brief
A patient with anti-CASPR1 antibody-mediated autoimmune nodopathy, unresponsive to standard treatments like intravenous immunoglobulin and plasma exchange, received a novel sequential therapy of efgartigimod followed by rituximab after one efgartigimod half-life. Over one year, the patient's serum anti-CASPR1 IgG levels normalized, and clinical scores improved, indicating effective B-cell depletion and symptom relief.
What made this case unusual
The case demonstrates the feasibility of administering rituximab after a shorter washout period from efgartigimod than traditionally expected, challenging conventional pharmacokinetic principles.
Diagnostic / clinical pearl
Clinicians should consider that the washout period for FcRn antagonists like efgartigimod may be shorter than five half-lives when planning sequential therapy with monoclonal antibodies.
Why it matters
This case highlights a potential modification in treatment protocols for autoimmune nodopathy, which could improve outcomes for patients who do not respond to standard therapies.